Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedApr 08, 2026
DataAggregated Company Financials
Companies9
  • 7D-0.8%
  • 3M-2.2%
  • 1Y34.8%
  • YTD2.0%

The Pharma industry is up 2.4% in the last week, with Sandoz Group up 2.3%. In the last 12 months, the industry was up 41%. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 08 Apr 2026CHF 546.7bCHF 122.2bCHF 25.3b37.5x21.6x4.5x
Fri, 06 Mar 2026CHF 590.5bCHF 120.7bCHF 25.0b35.5x23.6x4.9x
Sun, 01 Feb 2026CHF 586.7bCHF 119.3bCHF 24.6b38x23.8x4.9x
Tue, 30 Dec 2025CHF 561.4bCHF 120.7bCHF 21.4b35.1x26.2x4.7x
Thu, 27 Nov 2025CHF 537.6bCHF 121.7bCHF 21.6b35.3x24.8x4.4x
Sat, 25 Oct 2025CHF 495.2bCHF 120.1bCHF 20.9b33.9x23.7x4.1x
Mon, 22 Sep 2025CHF 476.6bCHF 120.1bCHF 20.9b31.1x22.8x4x
Wed, 20 Aug 2025CHF 477.0bCHF 121.0bCHF 21.1b31.3x22.6x3.9x
Fri, 18 Jul 2025CHF 443.3bCHF 117.7bCHF 19.0b24.7x23.3x3.8x
Sun, 15 Jun 2025CHF 456.7bCHF 118.2bCHF 19.1b25.9x23.9x3.9x
Tue, 13 May 2025CHF 433.6bCHF 120.5bCHF 19.5b25.2x22.2x3.6x
Thu, 10 Apr 2025CHF 379.8bCHF 120.0bCHF 18.9b22.6x20.1x3.2x
Sat, 08 Mar 2025CHF 489.5bCHF 121.3bCHF 19.1b29.5x25.6x4x
Mon, 03 Feb 2025CHF 467.7bCHF 123.2bCHF 19.3b22.4x24.3x3.8x
Wed, 01 Jan 2025CHF 426.9bCHF 119.5bCHF 21.4b17.9x19.9x3.6x
Fri, 29 Nov 2024CHF 434.0bCHF 117.9bCHF 21.1b18.5x20.5x3.7x
Sun, 27 Oct 2024CHF 466.9bCHF 115.9bCHF 19.5b22x24x4x
Tue, 24 Sep 2024CHF 456.3bCHF 114.9bCHF 19.3b21.8x23.6x4x
Thu, 22 Aug 2024CHF 471.4bCHF 115.0bCHF 19.3b22.4x24.4x4.1x
Sat, 20 Jul 2024CHF 453.0bCHF 116.8bCHF 20.6b32.1x22x3.9x
Mon, 17 Jun 2024CHF 430.3bCHF 115.9bCHF 19.7b33.8x21.8x3.7x
Wed, 15 May 2024CHF 407.4bCHF 113.2bCHF 19.9b40.7x20.5x3.6x
Fri, 12 Apr 2024CHF 399.9bCHF 112.4bCHF 19.4b36.7x20.6x3.6x
Sun, 10 Mar 2024CHF 387.9bCHF 110.2bCHF 19.7b24x19.7x3.5x
Tue, 06 Feb 2024CHF 386.8bCHF 112.5bCHF 19.1b24.8x20.2x3.4x
Thu, 04 Jan 2024CHF 409.4bCHF 119.4bCHF 18.7b26.2x21.9x3.4x
Sat, 02 Dec 2023CHF 390.8bCHF 120.6bCHF 18.8b24.7x20.8x3.2x
Mon, 30 Oct 2023CHF 385.3bCHF 122.6bCHF 19.1b23.4x20.2x3.1x
Wed, 27 Sep 2023CHF 404.5bCHF 113.6bCHF 18.2b44.7x22.3x3.6x
Fri, 25 Aug 2023CHF 406.8bCHF 111.9bCHF 17.9b48.1x22.7x3.6x
Sun, 23 Jul 2023CHF 422.2bCHF 114.3bCHF 19.2b37.1x22x3.7x
Tue, 20 Jun 2023CHF 425.2bCHF 115.1bCHF 18.9b37.8x22.5x3.7x
Thu, 18 May 2023CHF 432.3bCHF 115.3bCHF 18.9b40x22.9x3.7x
Sat, 15 Apr 2023CHF 433.9bCHF 114.7bCHF 18.8b42.3x23.1x3.8x
Price to Earnings Ratio

23.1x


Total Market Cap: CHF 433.9bTotal Earnings: CHF 18.8bTotal Revenue: CHF 114.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.8x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 11% per year over the last three years.
  • Revenues for these companies have grown 2.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.088%
Healthcare-0.75%
Pharma-0.79%
Pharma-0.79%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SDZ Sandoz GroupCHF 63.182.3%
+CHF 623.1m		91.0%PE37.5x
COPN Cosmo PharmaceuticalsCHF 85.803.5%
+CHF 47.0m		76.2%PS14.4x
ADXN Addex TherapeuticsCHF 0.042.6%
+CHF 116.6k		-26.7%PS29.1x

Latest News

BIOV
CHF 26.50
BioVersys
7D
-7.3%
1Y
-26.4%
GALD
CHF 152.90
Galderma Group
7D
-0.3%
1Y
90.8%
NWRN
CHF 14.44
Newron Pharmaceuticals
7D
-4.7%
1Y
106.6%
SDZ
CHF 63.18
Sandoz Group
7D
2.3%
1Y
91.0%
ROP
CHF 311.30
Roche Holding
7D
-1.1%
1Y
24.5%

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?
NOVN
CHF 119.80
Novartis
7D
-0.9%
1Y
35.2%

NOVN: Dermatology Pipeline, RLT Expansion And Dividend Will Shape Balanced Returns

Analysts have modestly raised their Novartis price target from CHF 117.49 to CHF 121.50, citing updated assumptions for revenue growth, profit margins and future P/E as key drivers of the revision. What's in the News Cosentyx received US FDA approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor available for this group and expanding Novartis' dermatology footprint in a chronic inflammatory skin disease that often begins around puberty.
COPN
CHF 85.80
Cosmo Pharmaceuticals
7D
3.5%
1Y
76.2%

COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside

Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).
ADXN
CHF 0.04
Addex Therapeutics
7D
2.6%
1Y
-26.7%
DESN
CHF 333.00
Dottikon ES Holding
7D
-3.1%
1Y
86.5%